Guggenheim raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $92 from $90 and keeps a Buy rating on the shares following the company having reported positive Phase 3 data in Alexander disease. The firm, which estimates peak sales in the $100M-$150M range for this ultra-rare, fatal neurological disorder, contends that the company is well-positioned to exceed $3B in sales by the early 2030s.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Buy Rating for Ionis Pharmaceuticals: Promising Phase 3 Results for Zilganersen in Alexander Disease
- Buy Rating Affirmed for Ionis Pharmaceuticals Amid Promising Phase III Results for Zilganersen in Treating Alexander Disease
- Morning Movers: Metsera surges, Pfizer gains after acquisition pact
- Ionis Pharmaceuticals price target raised to $75 from $68 at Raymond James
- Ionis Pharmaceuticals Reports Positive Study Results for Zilganersen